Company: AVCRF
Filing Date: 2025-06-16
Form Type: 20-F
Source: 0001641172-25-015266
Chunk: 81

Company: Avricore Health Inc.
Filing Date: 2025-06-16
Form: 20-F
Item: Item 19
Chunk 81
---
 highly subjective estimates and assumptions, including the expected stock price volatility. Changes in the underlying assumptions
can materially affect the fair value estimates. There were no warrants issued for the years ended December 31, 2024 and 2023.

Avricore
Health Inc.

Notes
to the Consolidated Financial Statements

For
the years ended December 31, 2024, 2023 and 2022

(Expressed
in Canadian Dollars)

  11.      GENERAL                      
           AND ADMINISTRATIVE EXPENSES  
 ────────────────────────────────────────

SUMMARY OF GENERAL AND ADMINISTRATIVE EXPENSES

 ──────────────────────────────────────────────────────────────────────
  Bank                              10,347        6,008        5,421  
  Filing                            55,040       61,569       40,563  
  Insurance                         90,633       92,812       60,251  
  Office                            43,089       44,545       31,888  
  Payroll                           76,970       70,495       34,813  
  Regulatory                         1,131        7,373        5,238  
  Rent                              27,100       18,000       16,800  
  Travel                            95,338       35,317       55,170  
  Warranty                           9,750        3,250            -  
  General                          409,398      339,369      250,144  

  12.      RELATED                          
           PARTY TRANSACTIONS AND BALANCES  
 ────────────────────────────────────────────

For
the years ended December 31, 2024, 2023 and 2022, the Company recorded the following transactions with related parties:

  $ 15,100 in office rent (2023 – $ 6,000 and 2022-$ 6,000) to a company controlled by the Chief              
  Technology Officer of the Company.                                                                          
  $ 12,000 in office rent (2023 – $ 12,000 and 2022-$ 9,000) to a company controlled by the Chief             
  Financial Officer of the Company.                                                                           
  $ 317,978 for analyser quality control services (2023 - $ 231,393 and 2022- $ Nil) to a company controlled  
  by the Chief Technology Officer of the